After ISCHEMIA: is invasive physiology the only remaining gatekeeper for myocardial revascularization in chronic coronary syndromes?

Area of Science:

• Cardiology
• Clinical Trials
• Medical Diagnostics

Background:

• Chronic coronary syndrome management is evolving.
• The ISCHEMIA trial introduces new perspectives on treatment strategies.
• Established diagnostic tools like FFR are critical for patient care.

Purpose of the Study:

• To discuss the potential impact of the ISCHEMIA trial on chronic coronary syndrome.
• To highlight the role of coronary revascularization in patient management.
• To explore the complementary utility of invasive perfusion assessment (FFR) alongside trial findings.

Main Methods:

• Review of the International Study of Comparative Health Effectiveness With Medical And Invasive Approaches (ISCHEMIA).
• Discussion of invasive perfusion assessment techniques, specifically fractional flow reserve (FFR).
• Analysis of the diagnostic and management implications for patients with chronic coronary syndrome.

Main Results:

• The ISCHEMIA trial suggests a potential shift in treatment paradigms for chronic coronary syndrome.
• Coronary revascularization may be considered a secondary or 'bail-out' strategy.
• Fractional flow reserve (FFR) is a validated and essential tool for lesion-specific ischemia detection.

Conclusions:

• The ISCHEMIA trial findings necessitate a re-evaluation of current treatment guidelines.
• Integrating FFR with trial outcomes offers a comprehensive approach to managing chronic coronary syndrome.
• A balanced consideration of medical therapy, revascularization, and diagnostic tools is crucial.